Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 18/20 | 0.46 |
| ▸ | DDB1 | Q16531 | 11/20 | 0.46 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.41 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.41 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.41 |
| ▸ | TNF | P01375 | 1/20 | 0.40 |
| ▸ | IL1B | P01584 | 1/20 | 0.40 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29610374 | 1.00 | CRBN (0.46) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL26663778 | 0.84 | DDB1 (0.31) | CRBNDDB1 | |
| SCHEMBL24317674 | 0.83 | CRBN (0.54) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29532194 | 0.83 | CRBN (0.50) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24315733 | 0.83 | CRBN (0.50) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24315722 | 0.82 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL29532445 | 0.82 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24315801 | 0.82 | CRBN (0.53) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL26658401 | 0.82 | CRBN (0.51) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL24317607 | 0.80 | CRBN (0.51) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| CN-116783180-A | Tricyclic ligands for degradation of IKZF2 or IKZF4 | C4医药公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-9585884-B2 | Pyrimidinone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2017-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | CRBN 50/4885DDB1 215/4885IKZF3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.